{"schema_version":"1","generated_at":"2026-10-29T15:34:00.310Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/stanley-lipkowitz","json_url":"https://www.findmykol.com/kol/stanley-lipkowitz/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"stanley-lipkowitz","name":"Stanley Lipkowitz","credential":"MD","title":"Deputy Director, Center for Cancer Research (NCI)","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Breast","therapeutic_areas":["Breast"],"institution":"National Cancer Institute","institution_url":"https://www.findmykol.com/institution/national-cancer-institute","city":"Bethesda","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1255317657","orcid":"0000-0002-6103-2255","openalex":"A5062190577"},"summary":"Stanley Lipkowitz is Deputy Director, Center for Cancer Research (NCI) at National Cancer Institute. OpenAlex indexes 372 publications with 8,539 citations (h-index 43); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.","overview":{"text":"Stanley Lipkowitz, MD, PHD, is Deputy Director, Center for Cancer Research (NCI) at National Cancer Institute. The public record shows 372 publications with 8,539 citations (h-index 43), centered on Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Cancer Cells and Metastasis. It also documents an investigator role on 5 registered clinical trials.","bullets":["Most recent indexed publication: 2026 · Molecular cancer therapeutics","Top research focus: Cancer Immunotherapy and Biomarkers","5 registered trials on ClinicalTrials.gov"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":3,"topics":1,"strength":10},{"label":"Ovarian / Gynecologic Cancer","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Endometrial Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Fallopian Tube Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neoplasm Metastasis","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Brain Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Cancer Immunotherapy and Biomarkers","Breast Cancer Treatment Studies","Cancer Cells and Metastasis","HER2/EGFR in Cancer Research","Immune cells in cancer"],"works_with":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"National Cancer Institute (NCI)","trials":5,"payments":0,"mentions":5}]}},"scholarship":{"works_count":372,"cited_by_count":8539,"h_index":43,"i10_index":92,"pubmed_count":26,"latest_activity_year":2026,"source":"works"},"trials":{"count":5,"shown":3,"withheld":2,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07067138","title":"A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)","phase":"NA","status":"RECRUITING","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT07067138","trial_url":"https://www.findmykol.com/trial/NCT07067138"},{"nct":"NCT03394027","title":"ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma","phase":"PHASE2","status":"COMPLETED","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT03394027","trial_url":"https://www.findmykol.com/trial/NCT03394027"},{"nct":"NCT03190967","title":"T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery","phase":"PHASE1/PHASE2","status":"TERMINATED","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT03190967","trial_url":"https://www.findmykol.com/trial/NCT03190967"}],"source":"trials"},"payments":{"company_count":0,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1255317657","source":"payments"},"funding":{"award_count":0,"rows_total":60,"shown":3,"withheld":57,"rows":[{"project":"ZIASC007263","title":"Activating Cell Death Pathways in Breast Cancer Cells","fiscal_year":2025,"amount_usd":1213551,"organization":"DIVISION OF CLINICAL SCIENCES - NCI","source_url":"https://reporter.nih.gov/quickSearch/ZIASC007263"},{"project":"ZIABC010977","title":"Cbl Proteins as Regulators of Tyrosine Kinase Signaling","fiscal_year":2025,"amount_usd":772260,"organization":"DIVISION OF BASIC SCIENCES - NCI","source_url":"https://reporter.nih.gov/quickSearch/ZIABC010977"},{"project":"ZIABC011650","title":"Genomic characterization of breast cancer in high risk subsets of breast cancer","fiscal_year":2025,"amount_usd":220646,"organization":"DIVISION OF BASIC SCIENCES - NCI","source_url":"https://reporter.nih.gov/quickSearch/ZIABC011650"}],"source":"grants"},"congress":{"count":36,"years":{"first":2004,"last":2026},"societies":["AACR","ASCO","ESMO"],"shown":3,"withheld":33,"rows":[{"title":"Abstract LB056: Inhibiting WEE1 kinase enhances sensitivity of high grade serous ovarian cancer cells to the novel KIF18A inhibitor ATX020","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"late_breaking_abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-lb056","source_url":"https://doi.org/10.1158/1538-7445.am2026-lb056","status":"verified"},{"title":"Abstract 2944: Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate (IMMU-132) and Apo2L/TRAIL in triple negative breast cancer (TNBC)","society":"AACR","meeting":"AACR Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2025-2944","source_url":"https://doi.org/10.1158/1538-7445.am2025-2944","status":"verified"},{"title":"Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer","society":"AACR","meeting":"AACR (meeting unresolved)","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.ovarian25-pr004","source_url":"https://doi.org/10.1158/1538-7445.ovarian25-pr004","status":"verified"}],"source":"congress"},"publications":{"total":26,"shown":5,"withheld":21,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Preclinical modeling of trastuzumab deruxtecan in a mouse model of brain metastatic triple-negative breast cancer identifies two contributors to efficacy.","year":2026,"journal":"Molecular cancer therapeutics","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42929047/","status":"verified"},{"title":"DVT-primed neutrophils reshape the brain microenvironment to promote brain metastasis.","year":2026,"journal":"bioRxiv : the preprint server for biology","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42780036/","status":"verified"},{"title":"TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma.","year":2026,"journal":"bioRxiv : the preprint server for biology","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42845394/","status":"verified"},{"title":"Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclax.","year":2026,"journal":"Cell death & disease","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42373626/","status":"verified"},{"title":"Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.","year":2026,"journal":"bioRxiv : the preprint server for biology","types":["Journal Article","Preprint"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42239129/","status":"verified"}],"most_cited":{"total":372,"shown":5,"withheld":367,"rows":[{"title":"Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie Suppression of Growth Factor Signaling by c-Cbl/Sli-1","year":1999,"cited_by_count":1002,"type":"article","source_url":"https://doi.org/10.1016/s1097-2765(00)80231-2"},{"title":"Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer","year":2011,"cited_by_count":763,"type":"article","source_url":"https://doi.org/10.3233/bd-2010-0307"},{"title":"Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.","year":1999,"cited_by_count":552,"type":"article","source_url":"https://openalex.org/A5062190577"},{"title":"RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis","year":2011,"cited_by_count":415,"type":"review","source_url":"https://doi.org/10.1038/nrc3120"},{"title":"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study","year":2017,"cited_by_count":242,"type":"article","source_url":"https://doi.org/10.1200/jco.2016.72.1340"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Yoshimi Endo Greer","coauthored_works":75},{"name":"Christina M. Annunziata","coauthored_works":66},{"name":"Alexandra S. Zimmer","coauthored_works":62}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/stanley-lipkowitz-md","status":"verified"}]},"mentions":{"total":2,"shown":2,"rows":[{"url":"https://irp.nih.gov/blog/post/2019/10/irp-breast-cancer-researchers-answer-redditor-questions","platform":"other","status":"verified"},{"url":"https://www.cancer.gov/types/breast/research/experts-discuss-challenges-breast-cancer-research-video","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD and PhD, Weill Cornell Medical College","source_url":"https://www.wcpinst.org/wp-content/uploads/2019/04/May-12-2016-speaker-bios-FINAL.pdf","status":"provisional","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Attending clinician, NCI Intramural Oncology Service","source_url":"https://www.wcpinst.org/wp-content/uploads/2019/04/May-12-2016-speaker-bios-FINAL.pdf","status":"provisional","collected_at":"2026-10-28"},{"value":"Breast Cancer Clinic, Murtha Cancer Center at Walter Reed National Military Medical Center","source_url":"https://www.wcpinst.org/wp-content/uploads/2019/04/May-12-2016-speaker-bios-FINAL.pdf","status":"provisional","collected_at":"2026-10-28"}]},"media":{"total":1,"shown":1,"rows":[{"value":"Participated in NIH Reddit 'Ask Me Anything' on breast cancer (2019) with Alexandra Zimmer, MD","source_url":"https://irp.nih.gov/blog/post/2019/10/irp-breast-cancer-researchers-answer-redditor-questions","status":"verified","collected_at":"2026-10-28"}]}},"similar":[{"name":"Kevin Brown","slug":"kevin-brown","institution":"National Cancer Institute","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/kevin-brown","json_url":"https://www.findmykol.com/kol/kevin-brown/profile.json"},{"name":"Gregory Reaman","slug":"gregory-reaman","institution":"National Cancer Institute","specialty":"Pediatric Hematology-Oncology","url":"https://www.findmykol.com/kol/gregory-reaman","json_url":"https://www.findmykol.com/kol/gregory-reaman/profile.json"},{"name":"James Gulley","slug":"james-gulley","institution":"National Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/james-gulley","json_url":"https://www.findmykol.com/kol/james-gulley/profile.json"},{"name":"Robert Kreitman","slug":"robert-kreitman","institution":"National Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/robert-kreitman","json_url":"https://www.findmykol.com/kol/robert-kreitman/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Eric Winer","slug":"eric-winer","institution":"Yale School of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/eric-winer","json_url":"https://www.findmykol.com/kol/eric-winer/profile.json"},{"name":"Norman Wolmark","slug":"norman-wolmark","institution":"University of Pittsburgh","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/norman-wolmark","json_url":"https://www.findmykol.com/kol/norman-wolmark/profile.json"},{"name":"Hope Rugo","slug":"hope-rugo","institution":"City of Hope","specialty":"Hematology","url":"https://www.findmykol.com/kol/hope-rugo","json_url":"https://www.findmykol.com/kol/hope-rugo/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":2,"funding":57,"congress":33,"publications":21,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}